Scartozzi, Mario
 Distribuzione geografica
Continente #
NA - Nord America 2.320
AS - Asia 1.073
EU - Europa 583
SA - Sud America 285
AF - Africa 93
Continente sconosciuto - Info sul continente non disponibili 73
Totale 4.427
Nazione #
US - Stati Uniti d'America 2.249
SG - Singapore 366
CN - Cina 269
BR - Brasile 224
HK - Hong Kong 156
IT - Italia 152
VN - Vietnam 143
SE - Svezia 110
DE - Germania 63
GB - Regno Unito 58
CA - Canada 42
FR - Francia 42
CI - Costa d'Avorio 40
AR - Argentina 30
AT - Austria 29
RU - Federazione Russa 29
TR - Turchia 25
BG - Bulgaria 21
IN - India 20
NL - Olanda 19
BD - Bangladesh 18
FI - Finlandia 17
SN - Senegal 15
JP - Giappone 14
IQ - Iraq 13
ZA - Sudafrica 10
ES - Italia 9
ID - Indonesia 8
MX - Messico 8
VE - Venezuela 8
EC - Ecuador 7
UA - Ucraina 7
EG - Egitto 6
NG - Nigeria 6
PK - Pakistan 6
UZ - Uzbekistan 5
AL - Albania 4
CL - Cile 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
KE - Kenya 4
KR - Corea 4
LT - Lituania 4
PA - Panama 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
MY - Malesia 3
NI - Nicaragua 3
PE - Perù 3
PH - Filippine 3
RO - Romania 3
SA - Arabia Saudita 3
UY - Uruguay 3
AO - Angola 2
BE - Belgio 2
BS - Bahamas 2
ET - Etiopia 2
IE - Irlanda 2
JM - Giamaica 2
KZ - Kazakistan 2
MA - Marocco 2
NP - Nepal 2
PL - Polonia 2
PY - Paraguay 2
SI - Slovenia 2
SV - El Salvador 2
TN - Tunisia 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CG - Congo 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GD - Grenada 1
GH - Ghana 1
GT - Guatemala 1
IS - Islanda 1
JO - Giordania 1
KH - Cambogia 1
LB - Libano 1
LY - Libia 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TM - Turkmenistan 1
VG - Isole Vergini Britanniche 1
Totale 4.354
Città #
Ashburn 234
Singapore 212
San Jose 153
Hong Kong 152
Santa Clara 152
Chandler 102
Fairfield 81
Shanghai 80
Council Bluffs 70
Woodbridge 64
Dallas 58
New York 45
Abidjan 40
Los Angeles 40
Houston 39
Wilmington 36
Ho Chi Minh City 35
Boardman 34
Beijing 32
Cambridge 32
Seattle 32
Hanoi 29
Florence 28
Munich 24
Princeton 24
Vienna 24
Colorado Springs 23
Lawrence 21
Milan 21
Sofia 21
Lauterbourg 19
Istanbul 18
London 17
Buffalo 16
Medford 16
Dakar 15
São Paulo 15
Bremen 14
Ann Arbor 13
Ottawa 13
Frankfurt am Main 12
Montreal 12
Tokyo 12
Haiphong 10
Kent 9
Nuremberg 9
Redondo Beach 9
San Diego 9
Chicago 8
Des Moines 8
Turku 8
Atlanta 7
Baltimore 7
Dearborn 7
Miami 7
Poplar 7
Baghdad 6
Dong Ket 6
Fuzhou 6
Helsinki 6
Mexico City 6
Orem 6
Rio de Janeiro 6
Serra 6
Amsterdam 5
Bexley 5
Chennai 5
Guangzhou 5
Johannesburg 5
Lagos 5
Nanjing 5
Phoenix 5
Redwood City 5
Boston 4
Curitiba 4
Da Nang 4
Denver 4
Joinville 4
Lancaster 4
Memphis 4
Murcia 4
New Delhi 4
Ogden 4
Panama City 4
Porto Alegre 4
Quanzhou 4
Quito 4
San Francisco 4
Seacroft 4
Stockholm 4
Thái Nguyên 4
Tirana 4
Toronto 4
Augusta 3
Bitonto 3
Brasília 3
Brooklyn 3
Bảo Lộc 3
Bắc Ninh 3
Caracas 3
Totale 2.429
Nome #
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 296
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 194
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 186
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 157
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 154
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 154
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 142
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 142
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 140
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 139
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 138
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 135
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 131
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 130
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 125
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 123
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 120
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 119
Cholangiocarcinoma: new perspectives for new horizons 118
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 117
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 116
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 116
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 115
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 114
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 114
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 114
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 113
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 99
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 77
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 64
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 57
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 54
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 51
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 50
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 46
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 43
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 43
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 41
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 40
Totale 4.427
Categoria #
all - tutte 14.194
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.194


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022175 0 0 4 1 11 50 3 11 5 21 21 48
2022/2023396 38 60 32 24 40 45 6 24 88 2 31 6
2023/2024173 14 15 23 4 20 24 15 14 7 1 14 22
2024/20251.033 2 73 33 51 108 172 53 48 95 116 102 180
2025/20261.600 108 186 135 191 148 126 240 121 95 156 62 32
2026/2027650 80 466 104 0 0 0 0 0 0 0 0 0
Totale 4.427